# NEOGENOMICS, INC. (NEO) FY2026 Q2 P&L / Income Statement

- Company: NEOGENOMICS, INC. (NEO)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-07-28, accession number 0001077183-26-000059
- Page: https://plicit.ai/financials/neo/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/neo-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **NET REVENUE**: 201,656,000 US dollars
- **COST OF REVENUE**: 109,778,000 US dollars
- **GROSS PROFIT**: 91,878,000 US dollars
- **Total operating expenses**: 101,649,000 US dollars
- **LOSS FROM OPERATIONS**: negative 9,771,000 US dollars
- **Other income (expense), net (calculated)**: 11,597,000 US dollars
- **Income (loss) before taxes**: 1,826,000 US dollars
- **Income tax benefit**: negative 412,000 US dollars
- **Net income (loss)**: 2,238,000 US dollars
- **Client direct billing**: 137,956,000 US dollars
- **Commercial insurance**: 36,273,000 US dollars
- **Medicare and other government**: 27,427,000 US dollars
- **Self-pay**: 0 US dollars
- **General and administrative**: 63,613,000 US dollars
- **Research and development**: 10,761,000 US dollars
- **Sales and marketing**: 27,275,000 US dollars
- **Impairment charges (Note 5)**: 0 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.